G'day All, Would someone with a legal mind please cast an eye over the attached documents below and give an interpretation about this Licence agreement between CANNTAB Therapeutics and "Emblem Corp", particularly the Exclusive Collaboration and Part B (iii)? The way I read this is that Emblem Corp has the exclusive (Sole) rights to produce Canntabs Sustained release formulations.
Would this type of agreement allow other companies like CGB to produce the same products under Licence from "Emblem Corp"?
Info from Canntab annual report 31/05/2018 published on 19/01/2019, See attached link Below @Basileus @kates9999